Payment overview · 2025
General Payments
$1,282.77
63 reported records · 18 companies
Healthcare provider profile · identity verified
Mark E Velarde, MD
Allopathic & Osteopathic Physicians|Family Medicine · WESCOSVILLE, PA · NPI 1578513560
Verified facts
What the public records show
CMS Open Payments records show Mark E Velarde, MD received $1,282.77 in general payments during 2025 across 63 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $230.25 | 17.9% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $196.81 | 15.3% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $182.17 | 14.2% | 10 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $102.61 | 8.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.07 | 7.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.30 | 6.7% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $72.45 | 5.7% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.52 | 5.1% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $57.90 | 4.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.38 | 3.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.35 | 2.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.51 | 1.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.68 | 1.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.58 | 1.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.63 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.93 | 1.2% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $14.65 | 1.1% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $13.98 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,212.78 | 62 |
| Education | $69.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $182.17 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $182.17 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $120.62 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $117.57 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $103.75 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $77.46 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $68.94 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $68.94 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.61 | 3 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $65.52 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $57.90 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $55.60 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $52.26 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.39 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $30.35 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $30.35 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 448 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 413 | 82 |
| Gabapentin | Gabapentin | 317 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 279 | 64 |
| Lorazepam | Lorazepam | 216 | 33 |
| Lisinopril | Lisinopril | 202 | 52 |
| Divalproex Sodium | Divalproex Sodium | 192 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 176 | 35 |
| Simvastatin | Simvastatin | 172 | 47 |
| Furosemide | Furosemide | 164 | 33 |
| Eliquis | Apixaban | 163 | 24 |
| Sertraline Hcl | Sertraline Hcl | 151 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 36 |
| Losartan Potassium | Losartan Potassium | 145 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 33 |
| Metformin Hcl | Metformin Hcl | 140 | 37 |
| Potassium Chloride | Potassium Chloride | 138 | 18 |
| Omeprazole | Omeprazole | 119 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 26 |
| Buspirone Hcl | Buspirone Hcl | 100 | 17 |
| Famotidine | Famotidine | 98 | 17 |
| Mirtazapine | Mirtazapine | 95 | 19 |
| Alprazolam | Alprazolam | 87 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 16 |
| Lamotrigine | Lamotrigine | 85 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 18 |
| Trazodone Hcl | Trazodone Hcl | 84 | 15 |
| Olanzapine | Olanzapine | 76 | 12 |
| Latanoprost | Latanoprost | 75 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 70 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 12 |
| Clonazepam | Clonazepam | 67 | 11 |
| Warfarin Sodium | Warfarin Sodium | 67 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 11 |
| Risperidone | Risperidone | 62 | 13 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Meloxicam | Meloxicam | 50 | 24 |
| Levetiracetam | Levetiracetam | 47 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 46 | suppressed |
| Prednisone | Prednisone | 45 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Fenofibrate | Fenofibrate | 43 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Tradjenta | Linagliptin | 40 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 13 |
| Cephalexin | Cephalexin | 38 | 24 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 38 | suppressed |
| Rexulti | Brexpiprazole | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Loperamide | Loperamide Hcl | 37 | 22 |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 20 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Travoprost | Travoprost | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 18 |
| Lidocaine | Lidocaine | 28 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 27 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 17 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 14 |
| Carvedilol | Carvedilol | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,282.77 · 63 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Azstarys, CAPVAXIVE, Cologuard Collection Kit, EVENITY, FARXIGA, Fluad, Flucelvax, GARDASIL 9, GEMTESA, INSPIRE, JARDIANCE, MOUNJARO, NEFFY, NURTEC ODT, ONPATTRO, Ozempic, PAXLOVID, PROLIA, QULIPTA, RECORLEV, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error